Geron (GERN) Restructuring Costs (2012 - 2026)

Geron's (GERN) quarterly Restructuring Costs came in at -$157000.0 in Q2 2026, up 60.15% quarter-over-quarter from -$394000.0 in Q1 2026.

Analysis

Geron (GERN) Restructuring Costs (2012 - 2026) Analysis & Trends

Geron has disclosed Restructuring Costs across 4 years of filings, most recently posting -$157000.0 for Q2 2026.

In Q2 2026, Restructuring Costs changed N/A year-over-year to -$157000.0; the TTM figure through Jun 2026 stood at -$551000.0 (down 1243.9% YoY), while the FY2025 annual figure was $17.0 million, changed N/A from the prior year.
Restructuring Costs came in at -$157000.0 for Q2 2026 at Geron, up from -$394000.0 in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of -$157000.0 in Q2 2026 to a low of -$394000.0 in Q1 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn
10	Geron	914.60 Mn	613.75 Mn	-

Historic Data

Download Data